Share This Article:

Compassionate Use of Midostaurin in Myeloid and Lymphoid Neoplasia with FGFR1 Abnormality

Abstract Full-Text HTML XML Download Download as PDF (Size:2807KB) PP. 560-565
DOI: 10.4236/crcm.2014.310122    2,635 Downloads   3,261 Views   Citations

ABSTRACT

Background: Patients with stem cell myeloproliferative disorders have a particularly poor prognosis and limited treatment options, i.e. mainly aggressive chemotherapy or allogeneic stem cell transplantation. In 2004, Chen et al. reported a patient presenting a t(8;13) (p11;q12) cytogenic anomaly who responded positively to treatment with PKC412 (midostaurin), an oral multi-targeted tyrosine kinase inhibitor. Here, we report a second case treated with the above-mentioned drug. Patient: A 71-year-old woman was diagnosed as having chronic myelogenous leukaemia with eosinophilia secondary to t(8;13) with FGFR1 involvement. Due to her age, an allogeneic stem cell transplantation was not possible. Treatment: A treatment combining aggressive chemotherapy and midostaurin was explored. The patient received one cycle of hyper-CVAD chemotherapy followed by maintenance therapy with midostaurin. A relapse occurred after six months, and she was treated with four more cycles of hyper-CVAD chemotherapy. The patient entered a complete clinical, haematological and cytogenetic remission. A maintenance therapy with midostaurin continued for four months until she developed a chemoresistant relapse followed by acute leukaemia. Conclusion: This is the second case of a t(8;13) myeloid and lymphoid neoplasm with FGFR1 abnormalities treated successfully with midostaurin. Midostaurin is administered orally, allows for outpatient care and in this case showed only occasional and minimal side effects. The combination of hyper-CVAD and midostaurin extended survival by 21 months without allogeneic transplantation. This case further supports the possibility of using midostaurin for the treatment of other diseases with FGFR1 dysregulations; however, specific clinical trials are needed to confirm this hypothesis.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Beris, P. , Nagy, M. , Robert, D. , Samii, K. , McKee, T. and Schuler, J. (2014) Compassionate Use of Midostaurin in Myeloid and Lymphoid Neoplasia with FGFR1 Abnormality. Case Reports in Clinical Medicine, 3, 560-565. doi: 10.4236/crcm.2014.310122.

References

[1] Bain, B.J. (2010) Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB or FGFR1. Haematologica, 95, 696-698.
http://dx.doi.org/10.3324/haematol.2009.021675
[2] Valent, P., Horny, H.P., Bochner, B.S., Haferlach, T. and Reiter, A. (2012) Controversies and Open Questions in the Definitions and Classification of the Hypereosinophilic Syndromes and Eosinophilic Leukemias. Seminars in Hematology, 49, 171-181.
http://dx.doi.org/10.1053/j.seminhematol.2012.01.009
[3] Bain, B.J., Gilliland, D.G., Vardiman, J.W. and Horny, H.P. (2008) Chronic Eosinophilic Leukemia, Not Otherwise Specified. In: Swerdlow, S.H.C., Campo, E., Harris, N.L., et al., Eds., World Health Organization (WHO) Classification of Tumours, IARC Press, Lyon, 51-53.
[4] Bain, B.J., Gilliland, D.G., Vardiman, J.W. and Horny, H.P. (2008) Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB or FGFR1. In: Swerdlow, S.H.C., Campo, E., Harris, N.L., et al., Eds., World Health Organization (WHO) Classification of Tumours, IARC Press, Lyon, 51-53.
[5] Macdonald, D., Aguiar, R.C., Mason, P.J., Goldman, J.M. and Cross, N.C. (1995) A New Myeloproliferative Disorder Associated with Chromosomal Translocations Involving 8p11: A Review. Leukemia, 9, 1628-1630.
[6] Chen, J., Deangelo, D.J., Kutok, J.L., Williams, I.R., Lee, B.H., Wadleigh, M., Duclos, N., Cohen, S., Adelsperger, J., Okabe, R., Coburn, A., Galinsky, I., Huntly, B., Cohen, P.S., Meyer, T., Fabbro, D., Roesel, J., Banerji, L., Griffin, J.D., Xiao, S., Fletcher, J.A., Stone, R.M. and Gilliland, D.G. (2004) PKC412 Inhibits the Zinc Finger 198-Fibroblast Growth Factor Receptor 1 Fusion Tyrosine Kinase and Is Active in Treatment of Stem Cell Myeloproliferative Disorder. Proceedings of the National Academy of Sciences, 101, 14479-14484.
http://dx.doi.org/10.1073/pnas.0404438101
[7] Hatzimichael, E., Georgiou, G., Benetatos, L. and Briasoulis, E. (2013) Gene Mutations and Molecularly Targeted Therapies in Acute Myeloid Leukemia. American Journal of Blood Research, 3, 29-51.
[8] Savage, N., George, T.I. and Gotlib, J. (2013) Myeloid Neoplasms Associated with Eosinophilia and Rearrangement of PDGFRA, PDGFRB, and FGFR1: A Review. International Journal of Laboratory Hematology, 35, 491-500.
[9] Erba, H.P. (2010) Has There Been Progress in the Treatment of Older Patients with Acute Myeloid Leukemia? Best Practice Research Clinical Haematology, 23, 495-501.
http://dx.doi.org/10.1016/j.beha.2010.09.012
[10] Jackson, C.C., Medeiros, L.J. and Miranda, R.N. (2010) 8p11 Myeloproliferative Syndrome: A Review. Human Pathology, 41, 461-476.
http://dx.doi.org/10.1016/j.humpath.2009.11.003
[11] Valent, P., Gleich, G.J., Reiter, A., Roufosse, F., Weller, P.F., Hellmann, A., Metzgeroth, G., Leiferman, K.M., Arock, M., Sotlar, K., Butterfield, J.H., Cerny-Reiterer, S., Mayerhofer, M., Vandenberghe, P., Haferlach, T., Bochner, B.S., Gotlib, J., Horny, H.P., Simon, H.U. and Klion, A.D. (2012) Pathogenesis and Classification of Eosinophil Disorders: A Review of Recent Developments in the Field. Expert Review of Hematology, 5, 157-176.
http://dx.doi.org/10.1586/ehm.11.81
[12] Gotlib, J., Berube, C., Growney, J.D., Chen, C.C., George, T.I., Williams, C., Kajiguchi, T., Ruan, J., Lilleberg, S.L., Durocher, J.A., Lichy, J.H., Wang, Y., Cohen, P.S., Arber, D.A., Heinrich, M.C., Neckers, L., Galli, S.J., Gilliland, D.G. and Coutre, S.E. (2005) Activity of the Tyrosine Kinase Inhibitor PKC412 in a Patient with Mast Cell Leukemia with the D816V KIT Mutation. Blood, 106, 2865-2870.
http://dx.doi.org/10.1182/blood-2005-04-1568
[13] Fabbro, D., Ruetz, S., Bodis, S., Pruschy, M., Csermak, K., Man, A., Campochiaro, P., Wood, J., O’Reilly, T. and Meyer, T. (2000) PKC412—A Protein Kinase Inhibitor with a Broad Therapeutic Potential. Anti-Cancer Drug Design, 15, 17-28.
[14] Marte, B.M., Meyer, T., Stabel, S., Standke, G.J., Jaken, S., Fabbro, D. and Hynes, N.E. (1994) Protein Kinase C and Mammary Cell Differentiation: Involvement of Protein Kinase C Alpha in the Induction of Beta-Casein Expression. Cell Growth Differentiation, 5, 239-247.
[15] Growney, J.D., Clark, J.J., Adelsperger, J., Stone, R., Fabbro, D., Griffin, J.D. and Gilliland, D.G. (2005) Activation Mutations of Human c-KIT Resistant to Imatinib Mesylate Are Sensitive to the Tyrosine Kinase Inhibitor PKC412. Blood, 106, 721-724.
http://dx.doi.org/10.1182/blood-2004-12-4617
[16] Weisberg, E., Boulton, C., Kelly, L.M., Manley, P., Fabbro, D., Meyer, T., Gilliland, D.G. and Griffin, J.D. (2002) Inhibition of Mutant FLT3 Receptors in Leukemia Cells by the Small Molecule Tyrosine Kinase Inhibitor PKC412. Cancer Cell, 1, 433-443.
http://dx.doi.org/10.1016/S1535-6108(02)00069-7

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.